Table 3.
Comparison of baseline characteristics between COVID-19 survivors who did and did not have progression in glycaemic status over 1 year (n=42)
| Characteristic | Progressors | Non-progressors | P value |
|---|---|---|---|
| Number | 10 | 32 | |
| Age, yr | 62.0±7.5 | 61.3±8.9 | 0.811 |
| Male sex | 4 (40.0) | 17 (53.1) | 0.469 |
| BMI, kg/m2 | 24.0±3.1 | 24.4±2.6 | 0.681 |
| Fasting glucose, mmol/L | 5.01±0.34 | 5.06±0.47 | 0.746 |
| HbA1c, % | 5.36±0.21 | 5.54±0.21 | 0.074 |
| C-peptidea, nmol/L | 0.83 (0.61–0.98) | 0.64 (0.50–0.80) | 0.119 |
| HOMA-IRa | 1.52 (1.19–1.97) | 1.28 (0.90–2.19) | 0.706 |
| HOMA-βa | 88.6 (64.5–137.2) | 89.3 (60.7–121.2) | 0.588 |
| Matsuda indexa | 4.33 (3.55–7.17) | 6.65 (3.62–10.1) | 0.344 |
| COVID-19 severity | 0.030 | ||
| Mild | 4 (40.0) | 23 (71.9) | |
| Moderate | 3 (30.0) | 7 (21.9) | |
| Severe | 3 (30.0) | 2 (6.3) |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
COVID-19, coronavirus disease 2019; BMI, body mass index; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function.
a
Logarithmically transformed before analyses.